All In Biotech

NDA 017609 · Otsuka Icu Medcl

Normosol-R and Dextrose 5% In Plastic Container

Dextrose, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Gluconate · Injection

Last checked: Nov 19, 2026Latest source record: Sep 5, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1975

Aug 13, 1975

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,797

712 Phase 3, 359 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2025.

INDICATIONS AND USAGE Normosol-R and 5% Dextrose Injection is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. Normosol-R and 5% Dextrose also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. The solution is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 13, 1975 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; MAGNESIUM CHLORIDE 30MG/100ML; POTASSIUM CHLORIDE 37MG/100ML; SODIUM ACETATE 222MG/100ML; SODIUM CHLORIDE 526MG/100ML; SODIUM GLUCONATE 502MG/100ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,797 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.